Global Lipid-regulating Drugs Market is segmented By Type (Statins, Non-Statins), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Lipid-regulating Drugs Market Size
The Global Lipid-regulating Drugs Market size was valued US$ XX billion in 2022 and is estimated to reach US$ XX billion by 2031, growing at a CAGR of XX % during the forecast period (2024-2031).
Lipid regulators or lipid-regulating drugs are used to treat dyslipidemias, cardiovascular problems, osteoporosis and post-menopause complications.
Lipid-regulating Drugs Market Summary
|
Metrics |
Details |
|
CAGR |
High |
|
Size Available for Years |
2022-2031 |
|
Forecast Period |
2024-2031 |
|
Data Availability |
Value (US$) |
|
Segments Covered |
Type, Distribution Channel and Region |
|
Regions Covered |
North America, Europe, Asia-Pacific, South America and Middle East & Africa |
|
Fastest Growing Region |
Asia-Pacific |
|
Largest Region |
North America |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis and Other key Insights. |
For More Insights Request Free Sample
Lipid-regulating Drugs Market Dynamics
The lipid-regulating drugs market growth is driven by the increasing prevalence of diseases like Dyslipidemia, increasing geriatric population with cardiovascular diseases. In the elderly age group, lipid-altering medication has been proven to reduce cardiovascular risk.
Increasing prevalence of dyslipidemia cases globally, is expected to drive the growth in the forecast period
Dyslipidemia increases the chance of clogged arteries (atherosclerosis) and heart attacks, stroke or other circulatory concerns, especially in smokers. For instance, according to the National Center for Biotechnology Information, the prevalence of dyslipidemia was 34.0% overall, and 35.1%, and 26.3% in urban and rural areas, respectively. The prevalence of dyslipidemia was significantly higher in men than women (41.9% vs. 32.5%). Most (80%) lipid disorders are related to diet and lifestyle, although familial disorders (20%) are important as well.
Increasing prevalence of diabetes, is expected to drive the growth in the forecast period
The increasing prevalence of dyslipidemia in the diabetic population is expected to drive market growth. For instance, according to Yaru Li et al., published in PLoS One Journal 2018, dyslipidemia in the Chinese population was 39.9%, 46.8%, and 59.3% in the population with normal glucose prediabetes and type 2 diabetes mellitus (T2DM). Furthermore, the diabetic population has inclined over the years. As per a World Health Organization 2018 report, the number of people with diabetes has risen from 108 million in 1980 to 422 million in 2014, resulting in a rise in the global prevalence of diabetes among adults over 18 years of age from 4.7% in 1980 to 8.5% in 2014. Hence, the increasing prevalence of diabetes may result in an increasing prevalence of dyslipidemia.
Lack of awareness regarding the lipid regulators is likely to hamper the market growth
The prevalence of dyslipidemia among Chinese adults was high, but awareness, treatment, and control of dyslipidemia were low. Urban high-income earners and rural medium-income earners show higher prevalence. Low-income earners in urban and rural populations have the worst awareness treatment and control rate.
COVID-19 Impact Analysis On Lipid-regulating Drugs
The COVID-19 pandemic has led to the halt of several industrial processes causing unprecedented economic loss. However, pharmaceutical companies are thriving in these difficult times owing to the increasing demand for medication drugs across the globe. Likewise, the demand for these lipid-regulating drugs is experiencing considerable growth as major pharmaceutical companies focus on R&D activities to develop new drugs and cater to the demand for OTC drugs across several stores. The market is, therefore, expected to showcase positive growth during the forecast period.
Lipid-regulating Drugs Market Segment Analysis
The statins segment is expected to hold largest share in this market segment
The statins competitively inhibit the HMG-CoA reductase. Statins are more effective than other lipid-regulating drugs at lowering LDL-cholesterol concentration. Hence, the demand for statins is expected to increase as the prevalence of dyslipidemia increases.
In addition, the lipid regulatory market is being dominated by statin, and most of the statin drug patents are coming to an end, and there would be increased competition in the generics.
The retail pharmacies segment is expected to hold largest share in this market segment
The retail Pharmacies segment is expected to dominate during the forecast period. Lipid-regulating medications are easily, readily available in retail pharmacies as the generic medicine. Retail pharmacies offer convenient services, including home delivery of medicines and availability of all types of drugs and medicines. Moreover, consumer preference for easy availability of products due to busy lifestyles and hectic work schedules is anticipated to boost lipid-regulating drugs market growth.
Lipid-regulating Drugs Market Geographical Share
North America region holds the largest market share of global lipid-regulating drugs market
As per the OECD, the North American countries of the United States and Mexico have one of the highest prevalence’s of Obesity and Diabetes in the world. Furthermore, being overweight or obese increases the chances of developing the common type of diabetes, type 2 diabetes. As the presence of diabetes increases the risk of dyslipidemia, its prevalence is expected to increase.
However, the United States (US) and Canada have a developed and well-advanced health care system. These systems also encourage research and development activities. These policies encourage the global players to enter the US and Canada. As a result, these countries enjoy the presence of many major market players. Global players in the region meet as high and increasing demand; the market is further expected to increase.
Lipid-regulating Drugs Market Companies and Competitive Landscape
The global lipid-regulating drugs market is highly competitive with presence of global companies. Some of the key players which are contributing to the growth of the market include AbbVie, Amgen, Andrx Corporation, AstraZeneca, Bristol-Myers Squibb, Merck, Novartis, Pfizer, Teva Pharmaceuticals, Eli Lilly and Company, Yangtze River pharmaceutical, Shaanxi Yikanglong Biotechnology Co., Ltd, Chembon Pharmaceutical Co., Ltd. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market globally. For instance, On May 2021, Eli Lilly and Company completed Phase 1 study to evaluate the safety and tolerability of the study drug known as LY3202328 in healthy overweight participants in Part A, and those with dyslipidemia.
Market Key Companies to Watch
Amgen Inc
Company Overview: Amgen (Applied Molecular Genetics Inc.) is established in Thousand Oaks, California, on April 8, 1980, is one of the world's leading biotechnology companies. It is a values-based company deeply rooted in science and innovation to transform new ideas and discoveries into medicines for serious illnesses. Amgen's subsidiary deCODE Genetics, a global leader in human genetics, is a powerful differentiator, greatly improving identifying and validating human disease targets.
Product Portfolio: The Company’s portfolio comprised of include six therapeutic areas: cardiovascular disease, oncology, bone health, neuroscience, nephrology and inflammation.
Key Developments: In January 2020, Amgen completed Phase 3 trial study to evaluate the safety, tolerability, and efficacy on LDL-C of Evolocumab (AMG 145) in subjects with HIV and with Hyperlipidemia and Mixed Dyslipidemia.
Why Purchase the Report?
- Visualize the composition of the lipid-regulating drugs market segmentation by type, distribution channel and region highlighting the key commercial assets and players.
- Identify commercial opportunities in lipid-regulating drugs market by analyzing trends and co-development deals.
- Excel data sheet with thousands of data points of lipid-regulating drugs market - level 4/5 segmentation.
- PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
- Product mapping in excel for the key product of all major market players
The global lipid-regulating drugs market report would provide an access to an approx. 41 market data table, 54 figures and 200 pages.
Target Audience
- Service Providers/ Buyers
- Industry Investors/Investment Bankers
- Education & Research Institutes
- Research Professionals
- Emerging Companies
- Manufacturers
